Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (957)	5/31/1998 6:48:00 PM
From: Rob	Read Replies (1) \| Respond to of 1501

Sean, When I met with Dr.Salari several months ago, one of my first questions posed was how they planned to deal with this competitive threat. Tularik had forged many alliances and was (is) exceptionally well capitalized. Dr. Salari stated he had a contact at Tularik, was aware of their progress, and felt IZP had a comfortable ( 2-3 year) lead. He also smiled and stated that he was aware that their most promising molecule (for nf-kb inhibition) had just recently "blown up". I assumed this meant an unexpected pre-clinical toxicity, etc. Signal as you've indicated will be trading shortly. I had the opportunity at a recent investor's conference in Boston to speak briefly with Michael Murphy ( Cal Tech Stock Newsletter) regarding Signal. He said he'd be watching it closely as he does every biotech that gets their financing from Kleiner Perkins Caufield and Byers (one of the Microsofts of the VC world). I was most impressed with Ken Kam ( Technology Value Fund) who I also spoke briefly with. This guy has the #1 performing mutual fund (entire mutual fund universe, ~60% annualized)for the last three years. He and his partner invest in electronics and biotech. He seemed very eager to learn more about these companies. Hopefully their attention will ultimately benefit the share price of IZP. I think IZP is beginning to squander it's lead. It may not have it forever the way cash is flowing into competitors. If I were a major pharma I might wait to see who had the best molecule. Another point that needs to be addressed is the complacency regarding status updates on TB. It seems incomprehensible to me that a company that will soon be short on cash ( bad bargaining position, god forbid a another offering) gives such short shrift to a potentially valuable source of revenue. I can't seem to find anyone at IZP who really knows (or is willing to tell) where the product is in it's development process. I've been getting the canned "prototype stage" answer for the past six months. Something isn't right here. I'm starting to believe they REALLY don't know. I guess we can only wait patiently here in the dark (respect for shareholders?) and hope the new guy can complete a deal. Rob